Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2)

Acta Neurochirurgica, Supplementum

Volumn 115, Issue , 2013, Pages 27-31

  Macdonald, R Loch ^a   Higashida, Randall T ^b   Keller, Emanuela ^c   Mayer, Stephan A ^d   Molyneux, Andy ^e   Raabe, Andreas ^f   Vajkoczy, Peter ^g   Wanke, Isabel ^h,i   Bach, Doris ^j   Frey, Aline ^j   Marr, Angelina ^j   Roux, Sébastien ^j   Kassell, Neal ^k  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF BERN   (Switzerland)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁱ KLINIK HIRSLANDEN   (Switzerland)

^j ACTELION PHARMACEUTICALS LTD   (Switzerland)

^k UNIVERSITY OF VIRGINIA   (United States)

more..

Author keywords

Aneurysmal subarachnoid hemorrhage; Clazosentan; CONSCIOUS 2; Surgical clipping

Indexed keywords

CLAZOSENTAN; PLACEBO;

ADULT; AGED; ANEMIA; ANEURYSM CLIP; BRAIN INFARCTION; BRAIN VASOSPASM; CONFERENCE PAPER; CONTROLLED STUDY; DELAYED ISCHEMIC NEUROLOGICAL DEFICIT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GLASGOW OUTCOME SCALE; HUMAN; HYPOTENSION; LUNG COMPLICATION; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SUBARACHNOID HEMORRHAGE;

EID: 85052609863     PISSN: 00651419     EISSN: 00016268     Source Type: Book Series    
DOI: 10.1007/978-3-7091-1192-5_7     Document Type: Conference Paper

References (16)

1. Al-Khindi T, Macdonald RL, Schweizer TA (2010) Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke 41:e519-e5366
2. Cahill J, Zhang JH (2009) Subarachnoid hemorrhage: is it time for a new direction? Stroke 40:S86-S877
3. Crowley RW, Medel R, Kassell NF, Dumont AS (2008) New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage. Drug Discov Today 13:254-2600
4. Crowley RW, Medel R, Dumont AS, Ilodigwe D, Kassell NF, Mayer SA, Ruefenacht D, Schmiedek P, Weidauer S, Pasqualin A, Macdonald RL (2011) Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke 42:919-9233
5. Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van GJ (2007) Calcium antagonists for aneurysmal subarachnoid hemorrhage. Cochrane Database Syst Rev: CD0002777
6. Dreier JP, Woitzik J, Fabricius M, Bhatia R, Major S, Drenckhahn C, Lehmann TN, Sarrafzadeh A, Willumsen L, Hartings JA, Sakowitz OW, Seemann JH, Thieme A, Lauritzen M, Strong AJ (2006) Delayed ischaemic neurological de fi cits after subarachnoid hemorrhage are associated with clusters of spreading depolarizations. Brain 129:3224-32377
7. Egge A, Waterloo K, Sjoholm H, Solberg T, Ingebrigtsen T, Romner B (2001) Prophylactic hyperdynamic postoperative fl uid therapy after aneurysmal subarachnoid hemorrhage: A clinical, prospective, randomized, controlled study. Neurosurgery 49:593-6055
8. Etminan N, Vergouwen MD, Ilodigwe D, Macdonald RL (2011) Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis. J Cereb Blood Flow Metab 31:1443-14511
9. Macdonald RL, Pluta RM, Zhang JH (2007) Cerebral vasospasm after subarachnoid hemorrhage: The emerging revolution. Nat Clin Pract Neurol 3:256-2633
10. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, Frey A, Roux S, Pasqualin A (2008) Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): Randomized, double-blind, placebo-controlled phase 2 dose- fi nding trial. Stroke 39:3015-30211
11. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Frey A, Marr A, Roux S, Kassell NF (2010) Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: Rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials. Neurocrit Care 13:416-4244
12. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N (2011) Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping: A randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 10:618-6255
13. Mayer SA, Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, Claassen J, Du YE, Connolly ES Jr (2002) Global and domain-speci fi c cognitive impairment and outcome after subarachnoid hemorrhage. Neurology 59:1750-17588
14. Rabinstein AA, Lanzino G, Wijdicks EF (2010) Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid hemorrhage. Lancet Neurol 9:504-5199
15. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P (2005) Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: Results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 103:9-177
16. Vergouwen MD, Vermeulen M, Coert BA, Stroes ES, Roos YB (2008) Microthrombosis after aneurysmal subarachnoid hemorrhage: An additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab 28:1761-17700